Skip to content

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

ABOS Acumen Pharmaceuticals, Inc. Common Stock
$0.22 0.93% +0.00
Notify me if price changes either direction
Interactive Brokers Logotype

Buy ABOS stocks now with Interactive Brokers – the most advanced investment platform

Contents
  • Performance
  • Key stats
  • Financials
  • US politician trades

Acumen Pharmaceuticals, Inc. Common Stock (ABOS)

Loading

Key Stats

Market cap. 15.6M
Enterprise value -36814952
Trailing PE -0.10800000280142
Forward PE -0.43989477
PEG Ratio 0.0031930435610854
Enterprise to EBITDA 0.352
Price to book MRQ 0.44676408

Financials

Fiscal Year Ends 2025-12-31
Most Recent Quarter (MRQ) 2026-06-30
EBITDA -104670000
Diluted EPS TTM -1.55
Total Cash (MRQ) 78.6M
Current ratio (MRQ) 1.888
Operating Cash Flow (TTM) -87952000

ABOS trades by the US politicians

Percentage
0% 0 sells
100% 0 buys
Amount
$0 0 sells
$0 0 buys
In the last 0 months

Recent ABOS News

Home

IMPORTANT NOTICE

Finbold is a news and information website. This Site may contain sponsored content, advertisements, and third-party materials, for which Finbold expressly disclaims any liability.

RISK WARNING: Cryptocurrencies are high-risk investments and you should not expect to be protected if something goes wrong. Don’t invest unless you’re prepared to lose all the money you invest. (Click here to learn more about cryptocurrency risks.)

By accessing this Site, you acknowledge that you understand these risks and that Finbold bears no responsibility for any losses, damages, or consequences resulting from your use of the Site or reliance on its content. Click here to learn more.